Pharmaceutical and Medicine Market Size, Share, Growth Report by Radiant Insights, Inc

This company database offers valuable information on the top 1000 pharmaceutical and medicine producers in the world proving an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for key company information in a readily accessible and clearly presented format.

 

The database is essential for companies who want to find out more about the leading players in the market or to find and contact potential customers and partners.

 

Get access to the following information about the companies

Company name

Financial data

Number of employees

Contact details

 

For more information kindly visit: http://www.radiantinsights.com/research/global-database-of-the-top-1000-pharmaceutical-and-medicine-producers-company-names-financial-performance-and-contact-details

 

Reason To Buy

– Identify the major companies operating in the global market

– Understand the competitive landscape

– Easily find and contact potential customers and partners

– Benchmark one company’s performance to other players in the market

– Save time and money with the easy accessible key company information included in this database.

 

Table of Contents

This valuable company database contains the following information about the market players (when available):

 

Company name

Financial data

Number of employees

Contact details

 

The company database is in Excel format.

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

 

For more information visit: Radiant Insights

 

Contact:                                                  

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://sagarkadam.kinja.com/

Regeneron Pharmaceuticals, Inc. – Product Pipeline Market Review – 2015

Global Markets Direct’s, ‘Regeneron Pharmaceuticals, Inc. – Product Pipeline Review – 2015’, provides an overview of the Regeneron Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Regeneron Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/regeneron-pharmaceuticals-inc-product-pipeline-review-2015

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides brief overview of Regeneron Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

– The report reviews current pipeline of Regeneron Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects

– The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones

– Special feature on out-licensed and partnered product portfolio

– The report summarizes all the dormant and discontinued pipeline projects

– Latest company statement

– Latest news and deals relating to the Regeneron Pharmaceuticals, Inc.’s pipeline products

Reason to Buy

– Evaluate Regeneron Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

– Assess the growth potential of Regeneron Pharmaceuticals, Inc. in its therapy areas of focus

– Identify new drug targets and therapeutic classes in the Regeneron Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

– Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

– Develop strategic initiatives by understanding the focus areas of Regeneron Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Plan mergers and acquisitions effectively by identifying the most promising pipeline of Regeneron Pharmaceuticals, Inc.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

– Explore the dormant and discontinued projects of Regeneron Pharmaceuticals, Inc. and identify potential opportunities in those areas

– Avoid Intellectual Property Rights related issues

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

 

For more information visit: Radiant Insights

 

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://marketstudy.tumblr.com/

India Ulcerative Colitis Drug Market Size, Trend and Research Report 2022: Radiant Insights, Inc

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.

Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

It is worth noting that in India, the local drug companies produce their own biosimilars, without many regulatory guidelines or any regard for the patent protection of the marketed products.

For more information kindly visit: http://www.radiantinsights.com/research/pharmapoint-ulcerative-colitis-india-drug-forecast-and-market-analysis-to-2022

For the treatment of UC, Indian physicians rely heavily on non-pharmacological methods, such as dietary recommendations, and for pharmacologic therapy, they use generic products within the corticosteroids and 5-ASA classes. GlobalData’s physician survey showed that these drugs are the mainstay of treatment for mild to moderate UC in India, as well as at earlier lines of therapy for severe disease.

Scope

– Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

– Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.

– Sales forecast for the top drugs in India from 2012-2022.

– Analysis of the impact of key events as well the drivers and restraints affecting the India Ulcerative Colitis market.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return

– Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.

– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

– Make more informed business decisions from insightful and in-depth analysis of drug performance

– Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.

About Us

 

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Gout – Epidemiology Market Size, Trend and Forecast Report 2023: Radiant Insights, Inc

Gout is a type of inflammatory arthritis. The disease is triggered by the crystallization of uric acid within the joints and is associated with hyperuricemia, a condition in which the body either overproduces or under excretes uric acid. Attacks of gout are episodic in nature and although months may pass before the next attack occurs, the pain experienced during an attack can be debilitating. Men are at a higher risk for developing gout and the risk also increases with age, with a mean age at diagnosis for gout in both men and women of 61 years.

GlobalData epidemiologists forecast an increase in both the diagnosed incident cases and diagnosed prevalent cases of gout in the 6MM, from 1,374,065 diagnosed incident cases in 2013 to 1,649,065 diagnosed incident cases in 2023, at an annual growth rate (AGR) of 2.00%, and 13,750,047 diagnosed prevalent cases in 2013 to 17,625,944 diagnosed prevalent cases in 2023, at an AGR of 2.82%.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/epicast-report-gout-epidemiology-forecast-to-2023

This forecast is supported by age- and sex-specific data obtained from country-specific estimates from peer reviewed journal articles, in which the study populations were representative of the general population in the respective markets. GlobalData epidemiologists used historical diagnosed incidence and diagnosed prevalence data which were available for Italy and the UK, along with linear regression methods to forecast the age- and sex-specific diagnosed incidence and diagnosed prevalence for Italy and the UK through 2023.

The forecast provides the age- and sex-specific diagnosed incident cases and diagnosed prevalent cases of gout in each of the 6MM, with clinically relevant segmentations, which facilitate an in depth understanding of the emerging temporal trends, and informs strategies to improve the management of the disease. Additionally, GlobalData epidemiologists used the same methodology across the 6MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of gout across these markets.

Scope

– The Gout EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for gout in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, this report includes a 10-year epidemiological forecast for the diagnosed incident cases and the diagnosed prevalent cases of gout segmented by sex and age (in five-year age groups beginning at 20 years and ending at =85 years). The diagnosed prevalent cases are then further segmented by the number of cases of gout flares and tophaceous gout.

– The gout epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

 

Reasons to buy

– Develop business strategies by understanding the trends shaping and driving the global gout market.

– Quantify patient populations in the global gout market to improve product design, pricing, and launch plans.

– Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for gout therapeutics in each of the markets covered.

About Us

 

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Global Schizophrenia Drug Market Share, Size and Analysis Report 2022: Radiant Insights, Inc

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits.

WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease.

View Full Report with TOC @ http://www.radiantinsights.com/research/pharmapoint-schizophrenia-global-drug-forecast-and-market-analysis-to-2022

GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Highlights

 

Key Questions Answered

– What are the preferred antipsychotic therapies for each country?

– The developmental pipeline consists of LAI antipsychotics that address medication compliance concerns. Which of these LAIs will attain high sales revenues during 2012-2022 and in which markets?

– Will LAI antipsychotics face adoption challenges in the market? What is the projected uptake of new LAIs, such as Otsuka/Lundbeck’s Abilify Maintena and Alkermes’ Aripiprazole lauroxil, over the forecast period?

– How large an impact will bitopertin and EVP-6124 have on the schizophrenia market? What do key opinion leaders think of these treatment approaches?

– What governmental and industry developments are likely to affect healthcare access and treatment rates in the markets researched? Which is the largest growth market globally?

Key Findings

– Country-specific mental health policy heavily influences antipsychotics prescribing patterns and sales in the marketplace.

– The impact of negative and cognitive symptom therapies in the marketplace will be challenging without the use of biomarkers and laboratory measurements that can demonstrate a patient’s response to treatment.

– Patient and prescriber endorsements of new and existing LAIs, in particular, atypical LAI antipsychotics, are anticipated to dramatically influence market growth.

– Major players will leverage their R&D, manufacturing, and distribution networks to maintain their stakes in the market.

Scope

– Overview of schizophrenia, including etiology, general symptoms, and country-specific treatment recommendations and compliance data.

– Annualized schizophrenia market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to 2022.

– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the schizophrenia market.

– Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically as Otsuka/Lundbeck’s Abilify Maintena and Alkermes’ Aripiprazole lauroxil.

– Analysis of the current and future market competition in the global schizophrenia drug market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

– Develop business strategies by understanding the trends shaping and driving the schizophrenia market.

– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia market in the future.

– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

– Track drug sales in the global schizophrenia market from 2012-2022.

– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

About Us

 

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Lennox-Gastaut Syndrome For Clinical Trials Market H1, 2015: Radiant Insights, Inc

GlobalData’s clinical trial report, “Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015” provides data on the Lennox-Gastaut Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lennox-Gastaut Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lennox-Gastaut Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/lennox-gastaut-syndrome-global-clinical-trials-review-h1-2015

Scope

– Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each

– Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

– Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons To Buy

– Understand the dynamics of a particular indication in a condensed manner

– Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

– Obtain discontinued trial listing for trials across the globe

– Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Frontier Pharma: Prostate Cancer – Identifying and Commercializing First-in-Class Innovation By Radiant Insights, Inc

Summary

Exceptionally Large and Innovative Pipeline

The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; GBI Research analysis identified 174 first-in-class programs in the prostate cancer pipeline, acting on 122 first-in-class molecular targets.

This accounts for some 36% of all products with a disclosed molecular target and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as, despite the high attrition rate in prostate cancer, it is highly likely many of the first-in-class technologies will reach the market over the coming decade and may transform the clinical and commercial landscape.

Alignment of First-in-Class Molecular Target with Disease Causation

One of the key trends in oncology and in prostate cancer in particular over the last decade is the clinical and commercial impact of targeted therapies designed to target proteins in signaling pathways that are strongly associated with disease progression. By aligning the molecular targets for therapeutic intervention with disease causation and/or propagation, these therapies limit the systemic cytotoxic effects whilst inhibiting tumor-promoting signaling pathways. Such strategies thereby typically achieve superior efficacy and safety profiles.

Our proprietary analyses demonstrate significant levels of differentiation as to how well the first-in-class products and their respective molecular targets align to underlying gene and protein level mutations and dysfunction. More advanced analytics further substantiated these findings as strong levels of differentiation in the scientific and clinical rationale for first-in-class molecular targets emerged. Furthermore, clear frontrunners were identified by integrating analyses to assess the accessibility of molecular targets for therapeutic compounds, the size of the target patient population that would benefit from therapeutic intervention, and the expected positioning of the first-in-class products based on the molecular targets and mechanisms of action of currently marketed products.

These insights and a detailed review of the available evidence from scientific studies substantiate the perspective that first-in-class-product technology in its own right is not sufficient to offer a compelling scientific and clinical rationale. However, a range of products offer very significant scientific and clinical promise and could therefore result in a strong commercial proposition with the prospect of clinically and commercially transformative products in the future.

For more information kindly visit: http://www.radiantinsights.com/research/frontier-pharma-prostate-cancer-identifying-and-commercializing-first-in-class-innovation

A Deals Landscape with Numerous Investment Opportunities

Analysis has confirmed that 169 of the 174 first-in-class products have not been involved in a licensing or co-development deal. Although many act on targets that are not yet strongly substantiated in terms of their therapeutic potential in prostate cancer in clinical studies, there are many which are supported by promising in vivo and in vitro preclinical evidence, and as such are highly promising prostate cancer therapies. Indeed, breakthrough innovations are highly desirable as an investment option.

However, most deals involving first-in-class products were either preclinical or Phase I development, whereas advance-in-class and addition-to-class product deals were typically made in Phases II and III, therefore showing significant differentiation. These findings have significant strategic implications for both biotech companies seeking to out-license products and firms with an interest in in-licensing first-in-class products with strong clinical and commercial prospects.

Scope

The report analyzes innovation in prostate cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzed the deals landscape surrounding first-in-class products in prostate cancer, and pinpoints opportunities for in-licensing. The report covers and includes –

– A brief introduction to prostate cancer, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms.

– The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline.

– Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.

– Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.

– Assessment of the licensing and co-development deal landscape for prostate cancer therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to –

– Understanding of the focal shifts in molecular targets in the prostate cancer pipeline.

– Understanding of the distribution of pipeline programs by phase of development, molecule type and molecular target.

– Access a scientific and clinical analysis of first-in-class developmental programs for prostate cancer, benchmarked against non-first-in-class targets.

– Access a list of the first-in-class therapies potentially open to deal-making opportunities

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://radiantinsights.weebly.com/